The effects of MEX3A knockdown on proliferation, apoptosis and migration of osteosarcoma cells

Wang, Bangmin; Hong, Zheping; Zhao, Chen; Bi, Qing; Yuan, Junhui; Chen, Jihang; Shen, Yi

doi:10.1186/s12935-021-01882-3

Cited by 6 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, a recent study has shown very low protein levels of RIG-I in GB specimens as well as in different human GB cell lines when compared to healthy brain tissue and non-tumor brain cell lines, respectively (Bufalieri et al, 2020 ). In this study, the authors have demonstrated that RIG-I protein levels are inversely associated with the expression of the RNA-binding Ubiquitin Ligase MEX3A, known to play an oncogenic role in several tumors (Jiang et al, 2012 ; Huang et al, 2017 ; Liang et al, 2020 ; Wang et al, 2020 , 2021 ; Wei et al, 2020 ).…”

Section: Agonists Of Rlrs As a Promising Therapeutic Strategy For Glioblastomamentioning

confidence: 82%

Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis

Bufalieri

Basili

Infante

2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Glioblastoma (GB) is an incurable form of brain malignancy in an adult with a median survival of less than 15 months. The current standard of care, which consists of surgical resection, radiotherapy, and chemotherapy with temozolomide, has been unsuccessful due to an extensive inter- and intra-tumoral genetic and molecular heterogeneity. This aspect represents a serious obstacle for developing alternative therapeutic options for GB. In the last years, immunotherapy has emerged as an effective treatment for a wide range of cancers and several trials have evaluated its effects in GB patients. Unfortunately, clinical outcomes were disappointing particularly because of the presence of tumor immunosuppressive microenvironment. Recently, anti-cancer approaches aimed to improve the expression and the activity of RIG-I-like receptors (RLRs) have emerged. These innovative therapeutic strategies attempt to stimulate both innate and adaptive immune responses against tumor antigens and to promote the apoptosis of cancer cells. Indeed, RLRs are important mediators of the innate immune system by triggering the type I interferon (IFN) response upon recognition of immunostimulatory RNAs. In this mini-review, we discuss the functions of RLRs family members in the control of immune response and we focus on the potential clinical application of RLRs agonists as a promising strategy for GB therapy.

show abstract

Section: Agonists Of Rlrs As a Promising Therapeutic Strategy For Glioblastomamentioning

confidence: 82%

Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis

Bufalieri

Basili

Infante

2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…According to previous studies, MEX3A is a potential oncogenic gene involved in carcinogenesis and progression of various types of tumors, including lung adenocarcinoma [ 9 ], breast cancer [ 13 ], and glioma [ 19 ]. Wang et al [ 8 ] found that MEX3A knockdown inhibits osteosarcoma cell proliferation, apoptosis, and migration. Wang et al [ 20 ] found the inhibitory effect of low MEX3A expression on the progression of pancreatic ductal adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…Mex3 RNA-binding family member A (MEX3A) was originally identified as a translational regulator in Caenorhabditis elegans that binds RNA [ 5 , 6 ]. MEX3A has been previously reported to act as oncogene in a variety of cancers, such as breast cancer [ 6 ], CRC [ 7 ] and osteosarcoma [ 8 ]. For example, Liang et al [ 9 ] found that MEX3A promotes lung adenocarcinoma metastasis by down-regulating LAMA2 and then activating PI3K/AKT pathway.…”

Section: Introductionmentioning

confidence: 99%

MEX3A promotes angiogenesis in colorectal cancer via glycolysis

Zhou

et al. 2023

Libyan Journal of Medicine

View full text Add to dashboard Cite

As a gastrointestinal malignancy, colorectal cancer (CRC) is a main cause of cancer-related deaths worldwide. Mex-3 RNA-binding family member A (MEX3A) is upregulated in multiple types of tumors and plays a critical role in tumor proliferation and metastasis. However, the function of MEX3A in CRC angiogenesis has not been fully understood. Hence, the aim of this study was to explore the role of MEX3A in CRC angiogenesis and investigate its underlying mechanisms. MEX3A expression in CRC was first investigated by bioinformatics means and then measured by qRT-PCR and Western blot. CCK-8 assay was employed to test cell viability. Angiogenesis assay was used to assess angiogenesis. The protein levels of VEGF, FGF and SDF-1 were evaluated using Western blot. The expression levels of MYC, HK2 and PGK1 were investigated by qRT-PCR. Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were determined by Seahorse XP 96. The levels of pyruvate, lactate, citric acid and malate were measured by corresponding kits. Bioinformatics analysis demonstrated high MEX3A expression in CRC tissues and MEX3A enrichment in glycolysis and angiogenesis pathways. Cell assays showed high MEX3A expression in CRC cells and its promoting effects in CRC cell proliferation and glycolysis as well as angiogenesis. Rescue experiment confirmed that glycolysis inhibitor 2-DG could offset the promoting effects of MEX3A on the proliferation, angiogenesis and glycolysis of CRC cells. In conclusion, MEX3A could facilitate CRC angiogenesis by activating the glycolytic pathway, suggesting that MEX3A may be a novel therapeutic target for CRC.

show abstract

“…Moreover, a few studies have evaluated the effect of MEX3A on tumors. Abnormal activation of MEX3A can promote tumor cell proliferation, metastasis, and migration in gastric cancer and pancreatic ductal adenocarcinoma, breast cancer, and osteosarcoma [6,[25][26][27]. For example, MEX3A may act as a tumor promoter for breast cancer by regulating PIK3CA.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of Prognostic Value of MEX3A and Its Relationship with Immune Infiltrates in Ovarian Cancer

Zhang

2021

Journal of Immunology Research

View full text Add to dashboard Cite

MEX3A is a critical RNA-binding ubiquitin ligase that is upregulated in various types of cancer. However, the correlations of MEX3A with prognosis and its molecular mechanism in ovarian cancer (OC) remain unclear. The expression level, prognostic values, and the genetic variations of MEX3A were analyzed via Gene Expression Profiling Interactive Analysis (GEPIA) Oncomine, Kaplan–Meier plotter, and cBioPortal. We used the LinkedOmics database to investigate the functions of MEX3A coexpressed genes and performed visualizing gene interaction network analysis on the GeneMANIA website. The correlations between MEX3A and cancer immune infiltration were analyzed by the Tumor Immune Estimation Resource (TIMER) site and the TISIDB database. Furthermore, in vitro analysis was performed to evaluate the biological functions of MEX3A in OC cells. Our study showed that the expression of the MEX3A in OC was higher than in normal tissues; it had the greatest prognostic value in OC, and strong physical interaction with PABPC1, LAMTOR2, KHDRBS2, and IGF2BP2, which indicated the association between MEX3A and immune infiltration. We also found that MEX3A was negatively related to infiltrating levels of several types of immune cells, including macrophages, neutrophils, dendritic cells (DCs), B cells, and CD8+ T cells. Additionally, in vitro experiments demonstrated that MEX3A promotes proliferation and migration in OC cells. Taken together, MEX3A might influence the biological functions of OC cells by regulating the immune infiltration in the microenvironment as a prognostic biomarker and a potential therapeutic target.

show abstract

The effects of MEX3A knockdown on proliferation, apoptosis and migration of osteosarcoma cells

Cited by 6 publications

References 31 publications

Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis

Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis

MEX3A promotes angiogenesis in colorectal cancer via glycolysis

Comprehensive Analysis of Prognostic Value of MEX3A and Its Relationship with Immune Infiltrates in Ovarian Cancer

Contact Info

Product

Resources

About